1. Home
  2. SBLX vs DRMA Comparison

SBLX vs DRMA Comparison

Compare SBLX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SBLX

StableX Technologies Inc.

HOLD

Current Price

$2.69

Market Cap

3.7M

ML Signal

HOLD

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.21

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBLX
DRMA
Founded
2017
2014
Country
United States
United States
Employees
58
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBLX
DRMA
Price
$2.69
$1.21
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
128.1K
1.9M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.11
$0.59
52 Week High
$7.85
$7.33

Technical Indicators

Market Signals
Indicator
SBLX
DRMA
Relative Strength Index (RSI) 54.37 41.16
Support Level $2.26 $1.11
Resistance Level $3.01 $2.29
Average True Range (ATR) 0.34 0.08
MACD 0.05 0.04
Stochastic Oscillator 74.68 39.58

Price Performance

Historical Comparison
SBLX
DRMA

About SBLX StableX Technologies Inc.

StableX Technologies Inc designs and manufactures compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, focusing on the manufacturing and sales of environmentally-conscious, minimal-footprint EVs.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology for patients suffering with acne. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin.

Share on Social Networks: